Vertex Software faces strong competition and slower growth, leading to a neutral rating. See why VERX stock remains pricey ...

Vertex Pharmaceuticals (VRTX) closed the latest trading day at $492.69, indicating a -1.96% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily loss of ...

Vertex Pharmaceuticals will not advance clinical trials of a treatment for Type 1 diabetes after efficacy data failed to support further clinical advancement.

Vertex Pharmaceuticals (VRTX) announced several updates on the company’s type 1 diabetes portfolio. Vertex has completed enrollment and dosing ...

On CNBC's “Halftime Report Final Trades ,” Jim Lebenthal of Cerity Partners said he is long-term bullish but a bit nervous ...

If you’re on the fence about investing in Vertex, Inc., Riot Platforms or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

In the latest quarter, 8 analysts provided ratings for Vertex (NASDAQ:VERX), showcasing a mix of bullish and bearish perspectives. The table below provides a concise overview of recent ratings by ...

Verve Ther­a­peu­tics has not es­caped the doom that seems to be en­gulf­ing the gene edit­ing sec­tor of late. The com­pa­ny ...

For the quarter ended December 2024, Vertex (VERX) reported revenue of $178.46 million, up 15.2% over the same period last year. EPS came in at $0.15, compared to $0.13 in the year-ago quarter.

Vertex has backed out of its in vivo gene editing collaboration with Verve Therapeutics before reaching the clinic. Verve, which attributed Vertex’s action to its changing R&D priorities, is ...